SMS Lifesciences India Ltd

Haleos Labs Ltd has announced the closure of its trading window for designated persons and connected individuals. The window will be shut from July 1, 2026, until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. This measure is in compliance with the company's 'Code of Conduct for Prevention Of Insider Trading'. The date for the board meeting to approve these financial results will be communicated separately.

Haleos Labs Ltd announced the reconstitution of its Board Committees following a change in Board composition. The company's Board of Directors, in a meeting held on May 29, 2026, approved changes to the Audit Committee, Nomination and Remuneration Committee, Corporate Social Responsibility (CSR) Committee, and Stakeholders Relationship (SHR) Committee. The reconstituted committees include a mix of independent and executive directors, with specific individuals appointed as Chairpersons and Members for each committee. The updated composition is available on the company's website.

Haleos Labs Ltd has appointed Suryanarayana & Suresh, Chartered Accountants, as its statutory auditors for a term of 5 years, starting from the conclusion of the 20th Annual General Meeting until the 25th Annual General Meeting, subject to shareholder approval. Additionally, Annapragada & Co. has been reappointed as Cost Auditors for the year 2026-27.

Haleos Labs Ltd has reappointed Mrs. Sudeepthi Gopineedi as a whole-time Director for a further period of 5 years, effective from September 2, 2026, subject to shareholder approval. The decision was based on recommendations from the Audit Committee and Nomination & Remuneration Committee. Mrs. Gopineedi's current tenure is up to September 1, 2026. She is liable to retire by rotation. Her profile and board composition details are available on the company website.

Mrs. Sundaramma Patilbandla has resigned from her position as an Independent Director of Haleos Labs Ltd, effective May 29, 2026, due to preoccupation and other professional commitments. Her resignation also entails her ceasing to be a member of the Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee. The Board of Directors has accepted her resignation and acknowledged her contributions. The company confirms that the Board's composition remains compliant with SEBI regulations.

Haleos Labs Ltd's board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They recommended a dividend of ₹1.501 (15%) per equity share for FY26, subject to shareholder approval. The board also noted the resignation of Independent Director Mrs. Sundaramma Patibandla, reconstituted sub-committees, and approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for 5 years, subject to shareholder approval. They approved overall managerial remuneration payable to Executive Director(s) and will conduct a postal ballot for shareholder approvals on key matters.

Haleos Labs Ltd. reminds shareholders to update their KYC details and announces the second 100-day campaign, "Saksham Niveshak," running from April 1, 2026, to July 9, 2026. The company sent a 6th reminder on May 25, 2026, through Aarthi Consultants Pvt Ltd, requesting shareholders to update their Bank, KYC, and Nomination details. Future dividend payments will be made electronically, discontinuing physical dividend warrants. Shareholders must update their bank details to receive dividends.

Haleos Labs Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. The board will also discuss and recommend a dividend for the financial year 2025-26, if any. The trading window will be closed until May 31, 2026.

Haleos Labs Ltd, formerly known as SMS Lifesciences India Limited, has disclosed that no shares were encumbered by promoters during the financial year 2025-26. This disclosure was made by Mr. TWSN Murthy on behalf of the promoter and promoter groups of the company. The company secretary has taken the disclosure on record and will disseminate it to all concerned parties.

TRUPTI RANJAN MOHANTY, related parties do not hold more than 10% of the total voting rights in the company, do not control the affairs of the company, do not have any special rights, not represented on the Board of Directors, do not act as key managerial personnel, are not wilful defaulters, and have no pending regulatory actions against them. They will comply with the conditions of reclassification for not less than 3 years.